United States

MJFF surpasses $50M with Brin Wojcicki Challenge

Thursday, February 28, 2013 08:00 AM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) it has completed and surpassed the $50 million Brin Wojcicki Challenge. Longtime foundation supporters Sergey Brin and Anne Wojcicki have matched more than $53 million in capacity-building gifts received by MJFF from January 1, 2011, to December 31, 2012.

More... »

KaloBios touts phase I/II results of KB002 in persistent asthma

Thursday, February 28, 2013 08:00 AM

KaloBios Pharmaceuticals reported data from its phase I/II study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003).

More... »

Qualicaps to expand N.C. facility, create 123 jobs

Wednesday, February 27, 2013 12:23 PM

Qualicaps, a manufacturer of gelatin capsules and wholly owned subsidiary of Qualicaps Group, plans to expand its facility in Whitsett, N.C.

More... »

De Silva named president and CEO of Endo Health Solutions

Wednesday, February 27, 2013 11:25 AM

Endo Health Solutions, a Malvern, Penn.-based diversified healthcare company, has named Rajiv De Silva as president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds David Holveck, who is retiring.

More... »

Intersect ENT raises $30M in Series D financing

Wednesday, February 27, 2013 10:58 AM

Intersect ENT, a Menlo Park, Calif.-based innovator in treatment solutions for ear, nose and throat clinicians and their patients, has completed the initial closing of a $30 million Series D round of funding. The financing will be used to continue the rapid commercial expansion in the U.S. for the company's PROPEL and PROPEL mini sinus implants and to fund clinical studies of the company's latest product, an office-based treatment for chronic sinusitis sufferers.

More... »

C-Path names Martha Brumfield as CEO

Tuesday, February 26, 2013 11:58 AM

The board of directors of the Critical Path Institute (C-Path), an independent, nonprofit organization, have named Martha Brumfield, Ph.D., as interim president and CEO. Brumfield, C-Path’s former director of international and regulatory programs, will take over immediately for Carolyn Compton, M.D., Ph.D. who will be assuming a new position at Arizona State University (ASU).

More... »

Covance, M2Gen to promote faster patient recruitment in biomarker-driven oncology trials

Tuesday, February 26, 2013 09:35 AM

Covance, a Princeton, N.J.-based provider of drug development services, has entered into an exclusive alliance and services agreement with M2Gen, a subsidiary of the Moffitt Cancer Center and developer of personalized cancer treatments.

More... »

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Lonza awarded NIH contract for research grade iPSCs

Monday, February 25, 2013 09:59 AM

The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza’s Walkersville, Md., facility a contract to generate induced pluripotent stem cells (iPSCs) for research purposes.  The contract is a three year agreement with a value up to $6.9 million dollars.                                      

More... »

FDA approves new treatment for late-stage breast cancer

Friday, February 22, 2013 12:41 PM

The FDA has approved Genentech’s Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

More... »